Trial Profile
A Phase IV Prospective Safety Surveillance Cohort Study Of ACAM2000 In Deploying Military Personnel.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 30 Sep 2020
Price :
$35
*
At a glance
- Drugs ACAM 2000 (Primary) ; Smallpox vaccine
- Indications Smallpox
- Focus Adverse reactions
- Sponsors Sanofi; Sanofi Pasteur
- 20 Sep 2020 Status changed to discontinued, according to results published in the Vaccine
- 20 Sep 2020 Results published in the Vaccine
- 18 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.